Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.53 |
| ▸ | SMO | Q99835 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496963 | 0.91 | MAPK14 (0.44) | MAPK14SMOMAPTKCNH2 | |
| SCHEMBL4415122 | 0.89 | MAPK14 (0.69) | MAPK14SMOMAPTLMNA | |
| SCHEMBL4408412 | 0.83 | MAPK14 (0.44) | MAPK14SMOMAPTKCNH2 | |
| SCHEMBL4408195 | 0.83 | PARP10 (0.48) | MAPK14SMOMAPTKCNH2 | |
| SCHEMBL5485509 | 0.83 | MAPK14 (0.49) | MAPK14SMOMAPTKCNH2 | |
| SCHEMBL14534689 | 0.82 | MAPK14 (0.65) | MAPK14SMOMAPTLMNA | |
| SCHEMBL5481396 | 0.82 | PARP10 (0.58) | MAPK14SMOKCNH2 | |
| SCHEMBL5489925 | 0.82 | PARP10 (0.48) | MAPK14SMOMAPTKCNH2 | |
| SCHEMBL14534669 | 0.81 | MAPK14 (0.44) | MAPK14SMOMAPTKCNH2 | |
| SCHEMBL14534447 | 0.80 | ALDH1A1 (0.51) | MAPK14SMOMAPTKCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035005-A2 | THERAPY USING CYTOKINE INHIBITORS | Kemia, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007146712-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-12-21 | — | — | WO | disclosed |